Colin Bristow analyst UBS

Currently out of the existing stock ratings of Colin Bristow, 108 are a BUY (61.71%), 67 are a HOLD (38.29%).

Colin Bristow

Work Performance Price Targets & Ratings Chart

Analyst Colin Bristow, currently employed at UBS, has had 68.31% of price targets met with an average potential upside of 36.92%, reached in 379 days on average. Previously, Colin Bristow worked at BAML.

Colin Bristow has documented 349 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NBTX, at 30-Apr-2026.

Wall Street Analyst Colin Bristow

Analyst best performing recommendations are on CADL.
The best stock recommendation documented was for BIIB (BIOGEN) on 6/2/2021. The price target of $311 was fulfilled within 5 days with a profit of $41.65 (15.46%), with a performance score of 30.93.

Average potential price target upside

ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BTAI GILD Gilead Sciences LLY MRK MTEM OMER PFE Pfizer PTCT SRPT VRTX Vertex Pharmaceuticals ABBV CCCC BMY RCKT ALXO IMVT REGN Regeneron Pharmaceuticals ABOS ENGN CADL NBTX

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 28-Jul-2017

$205

5 years 6 months 16 days ago
(05-May-2021)

3/5 (60%)

$35.09 (20.65%)

938

Hold Since 03-May-2021

$173

$156

5 years 6 months 18 days ago
(03-May-2021)

17/29 (58.62%)

$2.73 (1.60%)

650

Hold Since 04-Feb-2021

$190

$190

5 years 6 months 26 days ago
(26-Apr-2021)

11/14 (78.57%)

$23 (13.77%)

420

Buy Since 06-Sep-2019

$175

$165

5 years 9 months 17 days ago
(04-Feb-2021)

3/3 (100%)

$19.41 (12.48%)

397

Buy Since 17-Jul-2017

$166

$175

5 years 9 months 17 days ago
(04-Feb-2021)

32/33 (96.97%)

$10.41 (6.69%)

867

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Colin Bristow?

On 2012
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?